1.
Holt, R. I. G., Cockram, C., Flyvbjerg, A. & Goldstein, B. J. Textbook of Diabetes. (John Wiley & Sons, Incorporated, 2016).
2.
Holt, R. I. G. Textbook of diabetes. (Wiley-Blackwell, 2010).
3.
International Textbook of Diabetes Mellitus. (John Wiley & Sons, Incorporated, 2015).
4.
Type 1 diabetes in adults: diagnosis and management | Guidance and guidelines | NICE.
5.
Type 2 diabetes in adults: management | Guidance and guidelines | NICE.
6.
Chatterjee, S., Khunti, K. & Davies, M. J. Type 2 diabetes. The Lancet (2017) doi:10.1016/S0140-6736(17)30058-2.
7.
Atkinson, M. A., Eisenbarth, G. S. & Michels, A. W. Type 1 diabetes. The Lancet 383, 69–82 (2014).
8.
Matheus, A. S. de M. et al. Impact of Diabetes on Cardiovascular Disease: An Update. International Journal of Hypertension 2013, 1–15 (2013).
9.
Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes - ClinicalKey.
10.
Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes - ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0140673614607947.
11.
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R. & Neil, H. A. W. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. New England Journal of Medicine 359, 1577–1589 (2008).
12.
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet 352, 854–865 (1998).
13.
Effects of Intensive Glucose Lowering in Type 2 Diabetes. New England Journal of Medicine 358, 2545–2559 (2008).
14.
Turnbull, F. M. et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52, 2288–2298 (2009).
15.
Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes. New England Journal of Medicine 364, 818–828 (2011).
16.
Miller, M. E. et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 340, b5444–b5444 (2010).
17.
Duckworth, W. et al. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. New England Journal of Medicine 360, 129–139 (2009).
18.
Hayward, R. A. et al. Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine 372, 2197–2206 (2015).
19.
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine 358, 2560–2572 (2008).
20.
Wong, M. G. et al. Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. Diabetes Care 39, 694–700 (2016).
21.
Giorgino, F., Home, P. D. & Tuomilehto, J. Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear? Diabetes Care 39, S187–S195 (2016).
22.
Gæde, P., Lund-Andersen, H., Parving, H.-H. & Pedersen, O. Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes. New England Journal of Medicine 358, 580–591 (2008).
23.
The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. New England Journal of Medicine 329, 977–986 (1993).
24.
Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. New England Journal of Medicine 353, 2643–2653 (2005).
25.
Orchard, T. J. et al. Association Between 7 Years of Intensive Treatment of Type 1 Diabetes and Long-term Mortality. JAMA 313, (2015).
26.
Gæde, P. et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia 59, 2298–2307 (2016).
27.
Bianchi, C., Miccoli, R. & Del Prato, S. Hyperglycemia and Vascular Metabolic Memory: Truth or Fiction? Current Diabetes Reports 13, 403–410 (2013).
28.
Zinman, B. et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine 373, 2117–2128 (2015).
29.
Marso, S. P. et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine 375, 311–322 (2016).
30.
Boussageon, R. et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 343, d4169–d4169 (2011).
31.
Ray, K. K. et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. The Lancet 373, 1765–1772 (2009).
32.
Sultan, A. et al. Evolution of silent myocardial ischaemia prevalence and cardiovascular disease risk factor management in Type 2 diabetes over a 10-year period: an observational study. Diabetic Medicine (2017) doi:10.1111/dme.13364.
33.
Rawshani, A. et al. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. New England Journal of Medicine 376, 1407–1418 (2017).
34.
Sultan, A. et al. Evolution of silent myocardial ischaemia prevalence and cardiovascular disease risk factor management in Type 2 diabetes over a 10-year period: an observational study. Diabetic Medicine (2017) doi:10.1111/dme.13364.
35.
Soliman, E. Z. et al. Electrocardiographic Abnormalities and Cardiovascular Disease Risk in Type 1 Diabetes: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care 40, 793–799 (2017).
36.
Solomon, S. D. et al. Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017;40:412–418. Diabetes Care 40, 809.3-809 (2017).
37.
Mayer-Davis, E. J. et al. Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002–2012. New England Journal of Medicine 376, 1419–1429 (2017).
38.
Rawshani, A. et al. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. New England Journal of Medicine 376, 1407–1418 (2017).
39.
Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. New England Journal of Medicine 377, 300–301 (2017).
40.
Older antidiabetic drugs | The British Journal of Cardiology. https://bjcardio.co.uk/2018/03/older-antidiabetic-drugs/.
41.
Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?- ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354.
42.
Holman, R. R. et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine 377, 1228–1239 (2017).
43.
Pickering, R. J. et al. Recent novel approaches to limit oxidative stress and inflammation in diabetic complications. Clinical & Translational Immunology 7, (2018).
44.
Microvascular Complications and Foot Care. Diabetes Care 40, S88–S98 (2017).
45.
Valencia, W. M. & Florez, H. How to prevent the microvascular complications of type 2 diabetes beyond glucose control. BMJ (2017) doi:10.1136/bmj.i6505.
46.
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. The Lancet 375, 2215–2222 (2010).
47.
The changing face of diabetes complications - ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858716300109.
48.
Wong, M. G. et al. Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. Diabetes Care 39, 694–700 (2016).
49.
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death. New England Journal of Medicine 364, 829–841 (2011).
50.
Wannamethee, S. G., Shaper, A. G., Whincup, P. H., Lennon, L. & Sattar, N. Impact of Diabetes on Cardiovascular Disease Risk and All-Cause Mortality in Older Men: influence of age at onset, diabetes duration and established and novel rosk factors. Archives of Internal Medicine 171, (2011).
51.
Yudkin, J. S., Richter, B. & Gale, E. A. Intensified glucose control in type 2 diabetes—whose agenda? The Lancet 377, 1220–1222 (2011).
52.
Zhang, C.-Y. et al. Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: A meta-analysis. Annals of Medicine 42, 305–315 (2010).
53.
Ele Ferrannini. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. European Heart Journal 36, 2288–2296 (2015).
54.
Fox, C. S. et al. Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Diabetes Care 38, 1777–1803 (2015).
55.
Bianchi, C., Miccoli, R. & Del Prato, S. Hyperglycemia and Vascular Metabolic Memory: Truth or Fiction? Current Diabetes Reports 13, 403–410 (2013).
56.
Khunti, K. et al. Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study. Diabetes Care 38, 316–322 (2015).
57.
Hayward, R. A. et al. Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine 372, 2197–2206 (2015).
58.
Cefalu, W. T., Rosenstock, J., LeRoith, D., Blonde, L. & Riddle, M. C. Getting to the "Heart” of the Matter on Diabetic Cardiovascular Disease: "Thanks for the Memory”. Diabetes Care 39, 664–667 (2016).
59.
Black, J. A. et al. Change in cardiovascular risk factors following early diagnosis of type 2 diabetes: a cohort analysis of a cluster-randomised trial. British Journal of General Practice 64, e208–e216 (2014).
60.
Turnbull, F. M. et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52, 2288–2298 (2009).
61.
Zoungas, S. et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. The Lancet Diabetes & Endocrinology 5, 431–437 (2017).
62.
Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?- ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354.
63.
Saha, S. A. & Arora, R. R. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus – A pooled meta-analysis of randomized placebo-controlled clinical trials. International Journal of Cardiology 141, 157–166 (2010).
64.
Richard W. Nesto. LDL cholesterol lowering in type 2 diabetes: what is the optimum approach? Clinical Diabetes 26, (2008).
65.
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. New England Journal of Medicine 362, 1563–1574 (2010).
66.
Filippatos, T., Tsimihodimos, V., Pappa, E. & Elisaf, M. Pathophysiology of diabetic dyslipidaemia. Current Vascular Pharmacology 15, 1–1 (2017).
67.
Piepoli, M. F. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Atherosclerosis 252, 207–274 (2016).
68.
White, J. et al. Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes. JAMA Cardiology 1, (2016).
69.
Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data - ClinicalKey. https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858716000036.
70.
Hypertension: Clinical Management of Primary Hypertension in Adults | NICE guideline 127. August 2011. http://www.nice.org.uk/guidance/cg127.
71.
Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. New England Journal of Medicine 362, 1575–1585 (2010).
72.
Ferrannini, E. & Cushman, W. C. Diabetes and hypertension: the bad companions. The Lancet 380, 601–610 (2012).
73.
UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ : British Medical Journal 317, (1998).
74.
Whelton, P. K. Clinical Outcomes in Antihypertensive Treatment of Type 2 Diabetes, Impaired Fasting Glucose Concentration, and Normoglycemia. Archives of Internal Medicine 165, (2005).
75.
Barzilay, J. I. et al. Long-Term Effects of Incident Diabetes Mellitus on Cardiovascular Outcomes in People Treated for Hypertension: The ALLHAT Diabetes Extension Study. Circulation: Cardiovascular Quality and Outcomes 5, 153–162 (2012).
76.
Lindholm, L. H. et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. The Lancet 359, 1004–1010 (2002).
77.
Dahlöf, B. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. The Lancet 366, 895–906 (2005).
78.
Weber, M. A. et al. Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes. Journal of the American College of Cardiology 56, 77–85 (2010).
79.
Elliott, W. J. & Meyer, P. M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. The Lancet 369, 201–207 (2007).
80.
Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. New England Journal of Medicine 362, 1575–1585 (2010).
81.
Schrier, R. W., Estacio, R. O. & Jeffers, B. Appropriate Blood Pressure Control in NIDDM (ABCD) Trial. Diabetologia 39, 1646–1654 (1996).
82.
Bangalore, S., Kumar, S., Lobach, I. & Messerli, F. H. Blood Pressure Targets in Subjects With Type 2 Diabetes Mellitus/Impaired Fasting Glucose: Observations From Traditional and Bayesian Random-Effects Meta-Analyses of Randomized Trials. Circulation 123, 2799–2810 (2011).
83.
Effects of Different Blood Pressure–Lowering Regimens on Major Cardiovascular Events in Individuals With and Without Diabetes Mellitus. Archives of Internal Medicine 165, (2005).
84.
Personalised blood pressure ranges in type 2 diabetes?- ClinicalKey. https://www.clinicalkey.com/#!/content/journal/1-s2.0-S2213858718300020.
85.
Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials- ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300998.
86.
Personalised blood pressure ranges in type 2 diabetes?- ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300020.
87.
Solomon, S. D. et al. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care 40, 412–418 (2017).
88.
Cheung, N., Mitchell, P. & Wong, T. Y. Diabetic retinopathy. The Lancet 376, 124–136 (2010).
89.
Adamsson Eryd, S. et al. Risk of future microvascular and macrovascular disease in people with Type 1 diabetes of very long duration: a national study with 10-year follow-up. Diabetic Medicine 34, 411–418 (2017).
90.
Liew, G., Mitchell, P. & Wong, T. Y. Systemic management of diabetic retinopathy. BMJ 338, b441–b441 (2009).
91.
Romero-Aroca, P. et al. Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study. British Journal of Ophthalmology (2017) doi:10.1136/bjophthalmol-2016-310063.
92.
Romero-Aroca, P. et al. Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study. British Journal of Ophthalmology (2017) doi:10.1136/bjophthalmol-2016-310063.
93.
Romero-Aroca, P. et al. Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study. British Journal of Ophthalmology (2017) doi:10.1136/bjophthalmol-2016-310063.
94.
Solomon, S. D. et al. Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017;40:412–418. Diabetes Care (2017) doi:10.2337/dc17-er06e.
95.
Solomon, S. D. et al. Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017;40:412–418. Diabetes Care (2017) doi:10.2337/dc17-er06e.
96.
Rosenberg, J. B. & Tsui, I. Screening for Diabetic Retinopathy. New England Journal of Medicine 376, 1587–1588 (2017).
97.
Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes. New England Journal of Medicine 376, 1507–1516 (2017).
98.
Moreton, R. B. R., Stratton, I. M., Chave, S. J., Lipinski, H. & Scanlon, P. H. Factors determining uptake of diabetic retinopathy screening in Oxfordshire. Diabetic Medicine 34, 993–999 (2017).
99.
Melanie Davies. The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. Clinical Pharmacology : Advances and Applications 8, (2016).
100.
Navaneethan, S. D. et al. Diabetes Control and the Risks of ESRD and Mortality in Patients With CKD. American Journal of Kidney Diseases (2017) doi:10.1053/j.ajkd.2016.11.018.
101.
Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME - ClinicalKey.
102.
Webb, D. R. et al. Cardiovascular risk factors and incident albuminuria in screen-detected type 2 diabetes. Diabetes/Metabolism Research and Reviews (2016) doi:10.1002/dmrr.2877.
103.
Çakici, N., Fakkel, T. M., van Neck, J. W., Verhagen, A. P. & Coert, J. H. Systematic review of treatments for diabetic peripheral neuropathy. Diabetic Medicine 33, 1466–1476 (2016).
104.
Koye, D. N. et al. Incidence of chronic kidney disease among people with diabetes: a systematic review of observational studies. Diabetic Medicine (2017) doi:10.1111/dme.13324.
105.
Johal, S. et al. Pre-existing diabetes is a risk factor for increased rates of cellular rejection after kidney transplantation: an observational cohort study. Diabetic Medicine (2017) doi:10.1111/dme.13383.
106.
Clokie, M. et al. New horizons in the understanding of the causes and management of diabetic foot disease: report from the 2017 Diabetes UK Annual Professional Conference Symposium. Diabetic Medicine 34, 305–315 (2017).
107.
Game, F. Classification of diabetic foot ulcers. Diabetes/Metabolism Research and Reviews 32, 186–194 (2016).
108.
Jhamb, S., Vangaveti, V. N. & Malabu, U. H. Genetic and molecular basis of diabetic foot ulcers: Clinical review. Journal of Tissue Viability 25, 229–236 (2016).
109.
Boulton, A. J., Jeffcoate, W. J., Jones, T. L. & Ulbrecht, J. S. International collaborative research on Charcot’s disease - 2009. The Lancet 373, 105–106 (2009).
110.
Yavuz, M. et al. Plantar Shear Stress in Individuals With a History of Diabetic Foot Ulcer: An Emerging Predictive Marker for Foot Ulceration. Diabetes Care 40, e14–e15 (2017).
111.
P Naidoo. Lower limb complications of diabetes mellitus: a comprehensive review with clinicopathological insights from a dedicated high-risk diabetic foot multidisciplinary team. The British Journal of Radiology 88, (2015).
112.
Diabetic foot problems: prevention and management | Guidance and guidelines | NICE.
113.
Holt, R. I. G. Understanding of the causes and management of diabetic foot disease. Diabetic Medicine 34, 303–304 (2017).
114.
Jin, D., Xu, Y., Geng, D. & Yan, T. Effect of transcutaneous electrical nerve stimulation on symptomatic diabetic peripheral neuropathy: A meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice 89, 10–15 (2010).
115.
Çakici, N., Fakkel, T. M., van Neck, J. W., Verhagen, A. P. & Coert, J. H. Systematic review of treatments for diabetic peripheral neuropathy. Diabetic Medicine 33, 1466–1476 (2016).
116.
Foresta, C., Ferlin, A., Lenzi, A. & Montorsi, P. The great opportunity of the andrological patient: cardiovascular and metabolic risk assessment and prevention. Andrology (2017) doi:10.1111/andr.12342.
117.
Azmi, S. et al. Small-fibre neuropathy in men with type 1 diabetes and erectile dysfunction: a cross-sectional study. Diabetologia (2017) doi:10.1007/s00125-017-4245-z.
118.
Andersson, D. P. et al. Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction. Heart (2017) doi:10.1136/heartjnl-2016-310746.
119.
Omland, T., Randby, A., Hrubos-Strøm, H., Røsjø, H. & Einvik, G. Relation of Erectile Dysfunction to Subclinical Myocardial Injury. The American Journal of Cardiology 118, 1821–1825 (2016).
120.
Braffett, B. H., Wessells, H. & Sarma, A. V. Urogenital Autonomic Dysfunction in Diabetes. Current Diabetes Reports 16, (2016).
121.
Hotaling, J. M. et al. Cardiovascular Autonomic Neuropathy, Sexual Dysfunction, and Urinary Incontinence in Women With Type 1 Diabetes. Diabetes Care 39, 1587–1593 (2016).
122.
Giovanni Corona. Sexual Dysfunction in Type 2 Diabetes at Diagnosis: Progression over Time and Drug and Non-Drug Correlated Factors. PLoS ONE 11, (2016).
123.
Santi, D. et al. Six months of daily treatment with vardenafil improves parameters of endothelial inflammation and of hypogonadism in male patients with type 2 diabetes and erectile dysfunction: a randomized, double-blind, prospective trial. European Journal of Endocrinology 174, 513–522 (2016).
124.
Diabetes Mellitus Type 2: A Driving Force for Urological Complications - ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1043276016000321.
125.
Diabetes Mellitus Type 2: A Driving Force for Urological Complications - ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1043276016000321.
126.
Malavige, L. S., Wijesekara, P., Ranasinghe, P. & Levy, J. C. The association between physical activity and sexual dysfunction in patients with diabetes mellitus of European and South Asian origin: The Oxford Sexual Dysfunction Study. European Journal of Medical Research 20, (2015).
127.
Hotaling, J. M. et al. Cardiovascular Autonomic Neuropathy, Sexual Dysfunction, and Urinary Incontinence in Women With Type 1 Diabetes. Diabetes Care 39, 1587–1593 (2016).
128.
Dhatariya, K. K. & Vellanki, P. Treatment of Diabetic Ketoacidosis (DKA)/Hyperglycemic Hyperosmolar State (HHS): Novel Advances in the Management of Hyperglycemic Crises (UK Versus USA). Current Diabetes Reports 17, (2017).
129.
Assessing the relationship between admission glucose levels, subsequent length of hospital stay, readmission and mortality. Prime.
130.
Dhatariya, K. et al. NHS Diabetes guideline for the perioperative management of the adult patient with diabetes. Diabetic Medicine 29, 420–433 (2012).
131.
The evolution of diabetic ketoacidosis: An update of its etiology, pathogenesis and management - ClinicalKey. https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S0026049515003728.
132.
Scott, A. R. Management of hyperosmolar hyperglycaemic state in adults with diabetes. Diabetic Medicine 32, 714–724 (2015).
133.
Ian Blumer, MD, FRCPC1, 2, Maureen Clement, MD, CCFP3, ,. Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges. Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges.
134.
Chloe L. Edridge. Prevalence and Incidence of Hypoglycaemia in 532,542 People with Type 2 Diabetes on Oral Therapies and Insulin: A Systematic Review and Meta-Analysis of Population Based Studies. PLoS ONE 10, (2015).
135.
Khunti, K. et al. Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study. Diabetes Care 38, 316–322 (2015).
136.
Minimizing Hypoglycemia in Diabetes: Table 1. Diabetes Care 38, 1583–1591 (2015).
137.
Zaccardi, F. et al. Predicting hospital stay, mortality and readmission in people admitted for hypoglycaemia: prognostic models derivation and validation. Diabetologia (2017) doi:10.1007/s00125-017-4235-1.
138.
Zaccardi, F. et al. Risk factors and outcome differences in hypoglycaemia-related hospital admissions: A case-control study in England. Diabetes, Obesity and Metabolism (2017) doi:10.1111/dom.12941.
139.
Umpierrez, G. & Korytkowski, M. Diabetic emergencies — ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nature Reviews Endocrinology 12, 222–232 (2016).
140.
Umpierrez, G. & Korytkowski, M. Diabetic emergencies — ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nature Reviews Endocrinology 12, 222–232 (2016).
141.
Micha, R. et al. Association Between Dietary Factors and Mortality From Heart Disease, Stroke, and Type 2 Diabetes in the United States. JAMA 317, (2017).
142.
Khunti, K., Wolden, M. L., Thorsted, B. L., Andersen, M. & Davies, M. J. Clinical Inertia in People With Type 2 Diabetes: A retrospective cohort study of more than 80,000 people. Diabetes Care 36, 3411–3417 (2013).
143.
Paul, S. K., Klein, K., Thorsted, B. L., Wolden, M. L. & Khunti, K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovascular Diabetology 14, (2015).
144.
Nicolucci, A. & Standl, E. Antiplatelet Therapy for Every Diabetic Person? Diabetes Care 34, S150–S154 (2011).
145.
Seidu, S., Achana, F. A., Gray, L. J., Davies, M. J. & Khunti, K. Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials. Diabetic Medicine 33, 280–289 (2016).
146.
The Handbook for Vascular Risk Assessment, Risk Reduction and Risk Management - NHS Health Check. http://www.healthcheck.nhs.uk/news/the_handbook_for_vascular_risk_assessment_risk_reduction_and_risk_management/.
147.
Kunutsor, S. K., Seidu, S. & Khunti, K. Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials. Diabetic Medicine 34, 316–327 (2017).
148.
Fisher, L., Gonzalez, J. S. & Polonsky, W. H. The confusing tale of depression and distress in patients with diabetes: a call for greater clarity and precision. Diabetic Medicine 31, 764–772 (2014).
149.
Dana Dabelea. Association of Type 1 Diabetes vs Type 2 Diabetes Diagnosed During Childhood and Adolescence With Complications During Teenage Years and Young Adulthood. JAMA 317, 825–835.
150.
Personalised treatment targets in type 2 diabetes patients: The Dutch approach - ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1751991816300626.
151.
Dwamena, F. et al. Interventions for providers to promote a patient-centred approach in clinical consultations. in Cochrane Database of Systematic Reviews (John Wiley & Sons, Ltd, 1996). doi:10.1002/14651858.CD003267.pub2.
152.
Proceedings of the 5th International DAWN Summit 2014: Acting together to make person-centred diabetes care a reality - ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0168822715001862.
153.
Denig, P., Schuling, J., Haaijer-Ruskamp, F. & Voorham, J. Effects of a patient oriented decision aid for prioritising treatment goals in diabetes: pragmatic randomised controlled trial. BMJ 349, g5651–g5651 (2014).
154.
Abdul-Ghani, M. et al. Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? Diabetes Care 40, 813–820 (2017).
155.
Kaul, S. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care 40, 821–831 (2017).
156.
Ritholz, M. D., MacNeil, T. & Weinger, K. Difficult conversations: adults with diabetes and the discussion of microvascular complications. Diabetic Medicine (2017) doi:10.1111/dme.13419.
157.
Ritholz, M. D., MacNeil, T. & Weinger, K. Difficult conversations: adults with diabetes and the discussion of microvascular complications. Diabetic Medicine 34, 1447–1455 (2017).
158.
Textbook of diabetes. (Wiley Blackwell, 2017).
159.
Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?- ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354.
